High Cholesterol and Longevity: The Research That Doesn't Fit the Narrative

The conventional medical message on cholesterol is clear: lower is better, statins save lives, and high LDL is a primary cause of cardiovascular death. This narrative is so established that data pointing in the opposite direction is largely ignored outside of academic circles. Here's a look at that research.

The Jichi Medical School Cohort Study

Published in the Journal of Epidemiology (2011), the Jichi Medical School Cohort Study followed participants for a median of 23 years — one of the longest follow-up periods in the cholesterol literature.

Key findings:

  • People with low LDL-C had a 4× increased risk of dying from stroke
  • High cholesterol was protective against cardiovascular mortality, not harmful
  • People with "high" LDL (>100 mg/dL) had lower all-cause, cardiovascular, and cancer mortality compared to those with low LDL

This is not an outlier. Similar patterns have been observed across multiple long-term cohort studies, particularly in older populations.

Survival Curves: High Cholesterol Lives Longer

Older longitudinal data using Kaplan-Meier survival analysis showed that people with high total cholesterol survived substantially longer on average — including from cardiovascular causes. The survival curves diverged clearly, with higher cholesterol groups consistently showing longer survival across time horizons.

The Optimal Level Finding

A more recent study examining the relationship between total cholesterol and mortality found a U-shaped curve — both very low and very high cholesterol were associated with increased mortality, with the nadir around 220 mg/dL total cholesterol for both men and women. In other words, the "safest" level by mortality data was around what most guidelines currently recommend treating with statins.

The Nick Norwitz Natural Experiment

Nick Norwitz PhD (Harvard/Oxford trained metabolic scientist) has been running what he describes as a "natural experiment" for seven years: living with total cholesterol around 700 mg/dL and LDL between 500–600 mg/dL — levels associated with homozygous familial hypercholesterolemia (a genetic condition where patients can develop plaque in childhood).

After seven years of this, he underwent advanced coronary CT angiography — not just looking for calcified plaque but all plaque (soft + calcified), with AI-guided analysis capable of quantifying plaque down to the cubic millimeter.

His results: published in an open-access paper with extensive metabolic data tracked over time. The case adds to a growing literature on Lean Mass Hyper-Responders (LMHR) — individuals on low-carbohydrate diets who develop extremely high LDL despite lean physiques and optimal metabolic markers.

The comparison point: a plant-based influencer in his thirties, with far lower lifetime LDL exposure, was found to have 61.3 mm³ of quantified plaque using the same imaging technology.

The science of heart health is not settled. LDL is not a simple story.

Why Does This Research Get Ignored?

Several factors contribute:

The reverse causality problem: Low cholesterol can be a consequence of illness rather than a cause of longevity. People who are sick with cancer, liver disease, or other conditions often have naturally lower cholesterol. Studies that don't properly control for this can make low cholesterol appear harmful when it's actually a marker of pre-existing disease.

The "LDL vs. particle size" issue: Total LDL cholesterol is a crude measure. Small, dense LDL particles are more atherogenic than large, buoyant ones. High LDL numbers from large particles (common in low-carb dieters and LMHR) may not carry the same risk as high LDL from small particles.

Observational vs. causal data: Most cholesterol data is observational. Randomized controlled trials of statin therapy (which lower LDL) do show reduced cardiovascular events in high-risk populations — though effect sizes are often modest in absolute terms and less compelling in primary prevention. The existence of statin benefit doesn't resolve whether the absolute cholesterol number is the driver or something else.

What This Means Practically

This is not an argument to ignore cholesterol or stop statins. It is an argument for nuance that is currently missing from most clinical conversations:

  • Total cholesterol as a single number is a poor predictor of individual cardiovascular risk
  • Context matters enormously: metabolic health, particle size, inflammation, lifestyle
  • The relationship between cholesterol and mortality appears to be non-linear and population-dependent
  • Long-term cohort data repeatedly shows that in older populations, higher cholesterol is associated with longer survival

If your doctor tells you your cholesterol is too high without discussing ApoB, particle size, triglycerides, HDL, metabolic markers, and your specific risk profile, you're getting an incomplete picture.

Educational content based on published research. Not medical advice. Cardiovascular risk is multifactorial — work with a qualified clinician to interpret your individual data.

References:

  • Jichi Medical School Cohort Study, J Epidemiol. 2011;21(1):67–74
  • https://mdpi.com/2077-0383/13/24/7667
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC6367420/
  • Nick Norwitz LMHR study (open access) — linked via @nicknorwitz